U.S. FDA gives Moderna ‘fast track’ status for experimental coronavirus vaccine

The U.S. Food and Drug Administration (FDA) has given Moderna “fast track” designation for its experimental coronavirus vaccine, Reuters reported.
The “fast track” designation expedites the review of treatments and vaccines meant for serious conditions.